Stage 6 — Evaluate outcomes. Six hours after oxygen, therapeutic anticoagulation, and monitored inpatient care began, review the trend and choose the best interpretation and next step.
Trend
Choose your responses, then check the answer.
Explanation
Outcome evaluation Oxygenation, BP, HR, RR, symptoms, and lactate improve without observed bleeding. The client is responding clinically without current evidence of deterioration. Continue prescribed inpatient anticoagulation and monitoring, reassess for bleeding or decompensation, and plan transition to an appropriate oral regimen and follow-up when eligibility and discharge readiness are established. The CTPA confirms PE; improvement after treatment does not independently prove the diagnosis.
Step 1 — Compare the whole trajectory SpO2 rises while oxygen is reduced from 4 L to 2 L, BP increases without vasopressors, HR and RR fall, lactate normalizes, chest pain resolves, and no bleeding is observed. These findings support clinical improvement.
Step 2 — Do not over-interpret response The diagnosis was established by CT pulmonary angiography. Improvement after oxygen, anticoagulation, and supportive care evaluates the current plan; it does not serve as a diagnostic confirmation by itself.
Step 3 — Continue risk-appropriate care RV dysfunction and the initial low BP still justify inpatient monitoring. Continue the prescribed anticoagulant, watch for bleeding and recurrent instability, and select an oral regimen based on renal function, interactions, contraindications, adherence needs, and the discharge plan.
Key concept Evaluate outcomes by asking whether the client is improving, whether harm is emerging, and whether the next level of care remains appropriate.
Scenario (Stage 6 — Evaluate outcomes)Review the 6-hour trend after oxygen, therapeutic anticoagulation, and monitored inpatient care. Determine the response and the safest next step.
BackgroundNCJMM Stage 6 — Compare outcomes with baseline, identify adverse effects or deterioration, and update the continuity plan.
Outcome evaluation — Comparing post-intervention status to baseline goals to confirm therapy is working and to drive continuity-of-care decisions. Closes the NCJMM loop.
PE clinical recovery markers — Improving oxygenation on less supplemental oxygen, more stable BP, lower HR and RR, improving symptoms and lactate, and absence of treatment-related bleeding support a favorable early trend.
Transition to oral anticoagulation — For eligible patients, apixaban or rivaroxaban can be initiated without a parenteral lead-in; dabigatran and edoxaban require an initial parenteral-anticoagulant course. Agent selection remains patient-specific.